A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia
Issued Date
2023-04-01
Resource Type
ISSN
2667145X
Scopus ID
2-s2.0-85153188262
Journal Title
Journal of Mass Spectrometry and Advances in the Clinical Lab
Volume
28
Start Page
122
End Page
132
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Mass Spectrometry and Advances in the Clinical Lab Vol.28 (2023) , 122-132
Suggested Citation
Limsuwanachot N., Rerkamnuaychoke B., Niparuck P., Singdong R., Kongruang A., Hirunpatrawong P., Siriyakorn T., Yenchitsomanus P.t., Siriboonpiputtana T. A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia. Journal of Mass Spectrometry and Advances in the Clinical Lab Vol.28 (2023) , 122-132. 132. doi:10.1016/j.jmsacl.2023.04.002 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/81894
Title
A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia
Author's Affiliation
Other Contributor(s)
Abstract
Introduction: The therapeutic strategy and management of chronic myeloid leukemia (CML) have rapidly improved with the discovery of effective tyrosine kinase inhibitors (TKIs) to target BCR::ABL1 oncoprotein. However, nearly 30% of patients develop TKI resistance due to acquired mutations on the tyrosine kinase domain (TKD) of BCR::ABL1. Methods: We customized a mass array panel initially intended to detect and monitor the mutational burden of hotspot BCR::ABL1 TKD mutations accumulated in our database, including key mutations recently recommended by European LeukemiaNet. Additionally, we extended the feasibility of using the assay panel for the molecular classification of myeloproliferative neoplasms (MPNs) by incorporating primer sets specific for analyzing JAK2 V617F, MPL 515 K/L, and CALR types 1 and 2. Results: We found that the developed mass array panel was superior for detecting and monitoring clinically significant BCR::ABL1 TKD mutations, especially in cases with low mutational burden and harboring compound/polyclonal mutations, compared with direct sequencing. Moreover, our customized mass array panel detected common genetic alterations in MPNs, and the findings were consistent with those of other comparable assays available in our laboratory. Conclusions: Our customized mass array panel was practicably used as a routine robust assay for screening and monitoring BCR::ABL1 TKD mutations in patients with CML undergoing TKI treatment and feasible for analyzing common genetic mutations in MPNs.